SOBR Safe (SOBR) 10-K 17 Apr 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Apr. 17, 2017	Jun. 30, 2016
Document And Entity Information
Entity Registrant Name	TransBiotec, Inc.
Entity Central Index Key	1,425,627
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		100,000,000
Entity Public Float			$ 292,142
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets
Cash	$ 14,305	$ 7,851
Total current assets	14,305	7,851
Total Assets	14,305	7,851
Current liabilities
Accounts payable	349,849	622,129
Accrued interest payable	302,834	182,678
Notes payable - current - related parties	627,022	489,095
Notes payable - current, net	163,574	157,324
Derivative liability	180,038
Stock subscription payable	28,081	55,882
Related party payables	1,111,754	412,656
Other payables	263,033	242,612
Total current liabilities	3,026,185	2,162,376
Total Liabilities	3,026,185	2,162,376
Stockholders' Deficit
Preferred stock, $.00001 par value; 22,000,000 shares authorized, No shares issued or outstanding as of December 31, 2016 and December 31, 2015, respectively
Series A Convertible Preferred stock, $.00001 par value; 3,000,000 shares authorized, No shares issued or outstanding as of December 31, 2016 and December 31, 2015,
Common stock, $.00001 par value; 100,000,000 shares authorized; 67,751,068 and 60,251,068 shares issued and outstanding as of December 31, 2016 and December 31, 2015,	677	602
Additional paid in capital	14,095,430	14,353,628
Accumulated deficit	(17,064,086)	(16,468,956)
Total Transbiotec, Inc. stockholders' deficit	(2,967,979)	(2,114,726)
Noncontrolling interest	(43,901)	(39,799)
Total Stockholders' Deficit	(3,011,880)	(2,154,525)
Total Liabilities and Stockholders' Deficit	$ 14,305	$ 7,851

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Stockholders' Equity
Preferred stock par value	$ 0.00001	$ .00001
Preferred stock shares authorized	22,000,000	22,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Series A Convertible Preferred stock par value	$ 0.00001	$ .00001
Series A Convertible Preferred stock shares authorized	3,000,000	3,000,000
Series A Convertible Preferred stock shares issued	0	0
Series A Convertible Preferred stock shares outstanding	0	0
Common stock par value	$ 0.00001	$ .00001
Common stock shares authorized	100,000,000	100,000,000
Common stock shares issued	67,751,068	60,251,068
Common stock shares outstanding	67,751,068	60,251,068

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Consolidated Statements Of Operations
Revenues
Operating expenses:
Amortization & depreciation		454
General and administrative	396,143	446,983
Total operating expenses	396,143	447,437
Loss from operations	(396,143)	(447,437)
Other income (expense):
Gain/(Loss) on fair value adjustment - derivatives		25,456
Gain on debt reversal		485
Interest expense	(218,339)	(251,500)
Interest expense - beneficial conversion feature	15,250	(23,750)
Total other income (expense)	(203,089)	(249,309)
Loss before provision for income taxes	(599,232)	(696,746)
Net loss	(599,232)	(696,746)
Less: Net loss attributable to noncontrolling interest	4,102	5,012
Net loss attributable to TranBioTec, Inc.	$ (595,130)	$ (691,734)
Net loss per share
(Basic and fully diluted)	$ (0.01)	$ (0.01)
Weighted average number of common shares outstanding	67,320,740	59,261,114

Stockholders' Equity - TransBio

Stockholders' Equity - TransBiotec Inc. - USD ($)	Common Stock [Member]	Additional Paid-In Capital	Accumulated Deficit	Stockholders' Equity - TransBiotec Inc.	Total	Noncontrolling Interest
Beginning Balance, Shares at Dec. 31, 2014	58,416,660
Biginning Balance, Amount at Dec. 31, 2014	$ 585	$ 12,716,630	$ (15,777,222)	$ (3,060,007)	$ (3,094,794)	$ (34,787)
Stock issued for cash, Shares	834,408
Stock issued for cash, Amount	$ 7	1,495		1,502	1,502
Stock issued for services, Shares	1,000,000
Stock issued for services, Amount	$ 10	3,890		3,900	3,900
Paid in capital - beneficial conversion feature		25,000		25,000	25,000
Paid in capital - stock option expense		26,229		26,229	26,229
Paid in capital - Gain on related party debt conversion		1,472,384		1,472,384	1,472,384
Share exchange - noncontrolling interest					(5,012)	(5,012)
Paid in capital - Gain on related party forgiveness of debt		108,000		108,000	108,000
Net Loss			(691,734)	(691,734)	(691,734)
Ending Balance, Shares at Dec. 31, 2015	60,251,068
Ending Balance, Amount at Dec. 31, 2015	$ 602	14,353,628	(16,468,956)	(2,114,726)	(2,154,525)	(39,799)
Stock issued for cash, Shares	5,000,000
Stock issued for cash, Amount	$ 50	24,950		25,000	25,000
Stock conversion of note payable , Shares	2,500,000
Stock conversion of note payable, Amount	$ 25	9,725		9,750	9,750
Paid in capital - beneficial conversion feature		(21,500)		(21,500)	(21,500)
Paid in capital - stock option expense		(7,512)		(7,512)	(7,512)
Paid in capital - Gain on related party debt conversion		(83,823)		(83,823)	(83,823)
Share exchange - noncontrolling interest					(4,102)	(4,102)
Paid in capital - Reclassification of common share equivalents to derivative liabilities		(180,038)		(180,038)	(180,038)
Net Loss			(595,130)	(595,130)	(595,130)	(595,130)
Ending Balance, Shares at Dec. 31, 2016	67,751,068
Ending Balance, Amount at Dec. 31, 2016	$ 677	$ 14,095,430	$ (17,064,086)	$ (2,967,979)	$ (3,011,880)	$ (43,901)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating Activities:
Net loss	$ (595,130)	$ (691,734)
Adjustments to reconcile net loss to net cash provided by (used for) operating activities:
Amortization & depreciation		454
Change in fair value of derivative liabilities		(25,456)
Note payable beneficial conversion expense	(21,500)	23,750
Stock Options Expense	(7,512)	26,229
Stock based compensation	34,750
Changes in assets and liabilities:
Accounts payable	(272,280)	221,678
Stock subscription payable	(27,801)	27,815
Accrued interest payable	120,156	(136,726)
Related party payable	615,275	116,391
Notes payable	6,250	321,172
Other payable	16,319	(4,322)
Net cash used for operating activities	(131,473)	(120,749)
Financing Activities:
Net proceeds from shares issuances		1,502
Net proceeds from notes payable	137,927	154,315
Net payments from notes payable		(27,840)
Net cash provided by financing activities	137,927	127,977
Net Change In Cash	6,454	7,228
Cash At The Beginning Of The Period	7,851	623
Cash At The End Of The Period	14,305	7,851
Schedule Of Non-Cash Investing And Financing Activities
Debt converted to capital	9,750	1,472,384
Issuances of shares to settle accrued interest		3,900
Gain on forgiveness of debt - related party		108,000
Reclassification of common share equivalents to derivative liabilities	180,038
Shares issued for cash received in prior year	25,000
Supplemental Disclosure
Cash paid for interest	12,500	13,825
Cash paid for income taxes

NOTE 1. ORGANIZATION, OPERATION

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	TransBiotec, Inc. (“TransBiotec - DE”), formerly Imagine Media LTD., was incorporated August, 2007 in the State of Delaware. A corporation also named TransBiotec, Inc. (“TransBiotec - CA”) was formed in the state of California July 4, 2004. Effective September 19, 2011 TransBiotec - DE was acquired by TransBiotec - CA in a transaction classified as a reverse acquisition as the shareholders of TransBiotec - CA retained the majority of the outstanding common stock of TransBiotec - DE after the share exchange. The financial statements represent the activity of TransBiotec - CA from July 4, 2004 forward, and the consolidated activity of TransBiotec - DE and TransBiotec - CA from September 19, 2011 forward. TransBiotec - DE and TransBiotec - CA are hereinafter referred to collectively as the "Company". The Company has developed and plans to market and sell a non-invasive alcohol sensing system which includes an ignition interlock. The Company has not generated any revenues from its operations. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) as promulgated in the United States of America. Principles of consolidation The accompanying consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Transbiotec-CA. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Specifically, such estimates were made by the Company for the valuation of derivative liability, stock compensation and beneficial conversion feature expenses. Actual results could differ from those estimates. Cash The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents. The Company does not have any cash equivalents as of December 31, 2016 and December 31, 2015. Property and equipment Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life. Income tax The Company accounts for income taxes pursuant to ASC 740. Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Net loss per share The net loss per share is computed by dividing the net loss by the weighted average number of shares of common outstanding. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations. The Company has 41,384,476 stock options that can be converted to common stock if exercised. Financial Instruments Pursuant to ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets: quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist primarily of cash, accounts payable, accrued expenses, notes payable, related party payables, convertible debentures, and other payable. Pursuant to ASC 820 and 825, the fair value of our cash and cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2016 and 2015 on a recurring basis: December 31, 2015 Level 1 Level 2 Level 3 $ $ $ - - - - - - December 31, 2016 Level 1 Level 2 Level 3 $ $ $ Derivative liabilities (180,038 ) - - (180,038 ) - - Long-Lived Assets In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that may suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value. Beneficial Conversion Features From time to time, the Company may issue convertible notes that may contain an embedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method. Derivative Instruments The fair value of derivative instruments is recorded and shown separately under current liabilities. Changes in fair value are recorded in the consolidated statement of income under other income (expenses). The accounting treatment of derivative financial instruments requires that the Company record the embedded conversion option and warrants at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. As a result of entering into warrant agreements, for which such instruments contained a variable conversion feature with no floor, the Company has adopted a sequencing policy in accordance with ASC 815-40-35-12 whereby all future instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instruments are initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a weighted average Black-Sholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. Stock based compensation The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options and warrants to purchase shares of Company common stock at the fair market value at the time of the grant. Stock-based compensation cost to employees is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period under ASC718. For options issued to employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. Grants of stock to non-employees and other parties are accounted for in accordance with the ASC 505. Recent accounting pronouncement In August 2014, the FASB issued the FASB Accounting Standards Update No. 2014-15 “Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). In connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). The term probable is used consistently with its use in Topic 450, Contingencies. When management identifies conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern, management should consider whether its plans that are intended to mitigate those relevant conditions or events will alleviate the substantial doubt. The mitigating effect of management’s plans should be considered only to the extent that (1) it is probable that the plans will be effectively implemented and, if so, (2) it is probable that the plans will mitigate the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. If conditions or events raise substantial doubt about an entity’s ability to continue as a going concern, but the substantial doubt is alleviated as a result of consideration of management’s plans, the entity should disclose information that enables users of the financial statements to understand all of the following (or refer to similar information disclosed elsewhere in the footnotes): a. Principal conditions or events that raised substantial doubt about the entity’s ability to continue as a going concern (before consideration of management’s plans). b. Management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations. c. Management’s plans that alleviated substantial doubt about the entity’s ability to continue as a going concern. If conditions or events raise substantial doubt about an entity’s ability to continue as a going concern, but the substantial doubt is not alleviated after consideration of management’s plans, an entity should include a statement in the footnotes indicating that there is substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or available to be issued). Additionally, the entity should disclose information that enables users of the financial statements to understand all of the following: a. Principal conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. b. Management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations. b. Management’s plans that are intended to mitigate the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for the annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact of the adoptions of ASU 2014-15 on its consolidated financial statements. Minority interest (Noncontrolling interest) A subsidiary of the Company has minority members, representing ownership interests of 1.38% at December 31, 2016. The Company accounts for these minority, or noncontrolling interests pursuant to ASC 810-10-65 whereby gains and losses in a subsidiary with a noncontrolling interest are allocated to the noncontrolling interest based on the ownership percentage of the noncontrolling interest, even if that allocation results in a deficit noncontrolling interest balance

NOTE 2. GOING CONCERN

NOTE 2. GOING CONCERN	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
NOTE 2. GOING CONCERN	The Company has suffered recurring losses from operations and has a working capital deficit and stockholders' deficit, and in all likelihood, will be required to make significant future expenditures in connection with continuing marketing efforts along with general administrative expenses. As of December 31, 2016, the accumulated deficit is $17,064,086. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company may raise additional capital through the sale of its equity securities, through an offering of debt securities, or through borrowings from financial institutions or others. By doing so, the Company hopes to generate revenues from sales of its alcohol sensing and ignition lock systems. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern.

NOTE 3. RELATED PARTY TRANSACTI

NOTE 3. RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
NOTE 3. RELATED PARTY TRANSACTIONS	As of December 31, 2016 and December 31, 2015, the Company had payables due to officers, for accrued compensation and services of $1,111,754 and $412,656 respectively. On December 3, 2014, as part of a related party note payable agreement, the company agreed to convert 50% of certain outstanding accounts payable to common stock at a price of .09 per share. Per this agreement during the year ended December 31, 2016 and December 2015, approximately $61,009 of accounts payable is convertible into 677,871 shares and $86,624 is convertible into 962,494 shares. On July 1, 2015, the Company amended a note payable agreement with Lanphere Law Group, the company’s largest shareholder, which forgave $108,000 of the principal balance. The original principal balance on the note was $214,335 and the new principal balance on the note after the debt forgiveness is $106,335. The Company entered into a lease agreement with Lanphere Law Group, whereas the Company is the tenant and is paying monthly rent of $4,100.

NOTE 4. PROPERTY & EQUIPMENT

NOTE 4. PROPERTY & EQUIPMENT	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
NOTE 4. PROPERTY & EQUIPMENT	Property and equipment values recorded at cost are as follows: Dec. 31, 2016 Dec. 31, 2015 Office and Lab Equipment $ 32,127 $ 32,127 Furniture and fixtures 11,556 11,556 43,683 43,683 Less accumulated depreciation (43,683 ) (43,683 ) Property & Equipment, Net $ - $ - Depreciation expense for the year ended December 31, 2016 and 2015 was none, and $454, respectively.

NOTE 5. NOTES PAYABLE

NOTE 5. NOTES PAYABLE	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
NOTE 5. NOTES PAYABLE	December 31, 2016 December 31, 2015 Note payable to related party, unsecured, due 8/3/2012, interest rate 0%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 1,950 $ 1,950 Notes payable to related party, unsecured, due 12/31/2012, interest rate 0%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 11,810 $ 11,810 Note payable to related party, unsecured, $731,763, 5-years at 0% simple interest, due 7/1/2016, payment amounts vary each month, various late penalties. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 180,001 $ 180,001 Note payable to non-related party, unsecured, due 2/8/12, quarterly interest due, convertible at holder’s option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 10,000 $ 10,000 Note payable to non-related party, unsecured, due 11/8/12, quarterly interest due, convertible at holder’s option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 25,000 $ 25,000 Note payable to non-related party, unsecured, due 2/17/12, quarterly interest due, convertible at holder’s option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 25,000 $ 25,000 Note payable to non-related party, unsecured, due 2/18/12, quarterly interest due, convertible at holder’s option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 10,000 $ 10,000 Note payable to non-related party, unsecured, due 2/8/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 18%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 750 $ 750 Note payable to non-related party, unsecured, due 2/8/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 18%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 6,875 $ 6,875 Note payable to non-related party, unsecured, due 2/15/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 2,500 $ 2,500 Note payable to non-related party, unsecured, due 2/20/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 3,750 $ 3,750 Note payable to non-related party, unsecured, due 2/21/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE. share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 2,625 $ 2,625 Note payable to non-related party, unsecured, due 3/20/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 5,433 $ 5,433 Note payable to non-related party, unsecured, due 3/22/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 3,203 $ 3,203 Note payable to non-related party, unsecured, due 08/29/2013, simple interest 8% convertible at holder’s option at $.249 per TBT-CA share. Currently in default. Principal balance including interest to be paid upon receipt of equity funding and/or sales revenue. $ 15,000 $ 15,000 Note payable to related party, unsecured, due 03/01/2013, simple interest 9%. Currently in default. Principal balance including interest to be paid upon receipt of equity funding and/or sales revenue. $ 5,000 $ 5,000 Note payable to non-related party, unsecured, due 01/31/2013, simple interest 18%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 3,938 $ 3,938 Note payable to related party, unsecured, due 01/23/2014, simple interest 9% convertible at holder’s option at $.08 per TBT-DE share Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 50,000 $ 50,000 Note payable to related party, unsecured, due 07/02/2014, simple interest 9% convertible at holder’s option at $.04 per TBT-DE share Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 15,000 $ 15,000 Note payable to non-related party, unsecured, due 10/25/2013, simple interest 18% convertible at holder’s option at $.016 per TBT-DE share Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 2,000 $ 2,000 Note payable to non-related party, unsecured, due 12/27/2013, simple interest 9% quarterly, Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 15,000 $ 15,000 Note payable to non-related party, unsecured, due 9/11/2014, simple interest 10% yearly. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 5,000 $ 5,000 Note payable to related party, unsecured, due 11/12/2014, simple interest 9% convertible at holder’s option at $0.04 per TBT-DE share, currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 11,000 $ 11,000 Note payable to related party, unsecured, due 4/08/2015, simple interest 7% convertible at holder’s option at $0.0072 per TBT-DE share. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 15,000 $ 15,000 Note payable to related party, unsecured, due 8/05/2015, simple interest 7%, default interest 10%. Currently in default. Note contains a stock option. $ 10,000 $ 10,000 Note payable to related party unsecured, due 12/02/2015, simple interest 7%, default interest 10%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 106,334 $ 106,334 Note payable to non-related party, unsecured, due 3/26/2016, simple interest 8%, convertible at holder’s option at $0.0017 per TBT-DE share. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 25,000 $ 25,000 Note payable to related party, unsecured, due 4/11/2016, simple interest 10%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 13,000 $ 13,000 Note payable to related party, unsecured, due 11/11/2015, simple interest 10%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 45,000 $ 45,000 Note payable to non-related party, unsecured, due 11/11/2015, simple interest 10%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 2,500 $ 2,500 Note payable to related party, unsecured, due 12/26/2015, simple interest 10%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 25,000 $ 25,000 Note payable to related party, unsecured, due on demand, simple interest 10%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 15,277 $ - Note payable to related party, unsecured, due 7/23/2016, simple interest 10%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 15,000 $ - Note payable to related party, unsecured, due 5/1/2017, simple interest 7%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 3,750 $ - Note payable to related party, unsecured, due 11/9/2016, simple interest 7%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 15,000 $ - Note payable to related party, unsecured, due 7/26/2017, simple interest 7%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 3,900 $ - Note payable to related party, unsecured, due 8/03/2017, simple interest 7%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 20,000 $ - Note payable to related party, unsecured, due 9/28/2017, simple interest 7%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 20,000 $ - Note payable to related party, unsecured, due 10/05/2017, simple interest 7%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 20,000 $ - Note payable to related party, unsecured, due 11/15/2017, simple interest 7%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 25,000 $ - $ 790,596 $ 652,669 Less note discounts - (5,000 ) Less current - related parties (627,022 ) (489,095 ) Less current - non-related parties (163,574 ) (157,324 ) Long-term - related parties $ - $ - Required principal payments from December 31, 2016 forward are as follows: 2017 $ 790,596 2018 $ - 2019 $ - 2020 $ - 2021 $ - $ 790,596 Interest expense under notes payable for the years ended December 31, 2015 and December 31, 2016 was $198,327 and $121,338 respectively. During the years ended December 31, 2015 and December 31, 2016 the Company recognized a beneficial conversion feature expense on borrowing from convertible notes of $23,750 and none, respectively. In 2012 the company borrowed $110,000 under convertible notes with a variable conversion price based on a percentage of market price of which $103,395 were converted at December 31, 2014. The Company paid the remaining principal balance due on these convertible notes in January 2015. The Company determined that these notes have an embedded derivative and are therefore accounted for at fair value. The Company recorded fair market value adjustments for the years ended December 31, 2015 and December 31, 2016 of $(25,456) and none, respectively. The fair market value adjustments were based on the Black-Sholes method using the following assumptions: risk free rates ranging between 0.10% - 0.21%, dividend yield of 0%, expected life of 1 year, volatility between 128% - 354%. The fair value derivative liability under the notes as of December 31, 2015 and December 31, 2016 was none and none, respectively.

NOTE 6. DERIVATIVE LIABILITY

NOTE 6. DERIVATIVE LIABILITY	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
NOTE 6. DERIVATIVE LIABILITY	The Company determined approximately 15,643,398 stock options for common shares that were granted and a note convertible into 15,646,982 common shares during the year ended December 31, 2016 were in excess of the Company’s authorized shares amount of 100,000,000 which carry an embedded derivative and are therefore accounted for at fair value under ASC 820, Fair Value Measurements and Disclosures and ASC 825, Financial Instruments. Utilizing Level 1 Inputs, the Company recorded fair market value adjustments related to stock options for shares that were granted over the Company’s 100,000,000 authorized shares amount for year ended December 31, 2016 and December 31, 2015 of $180,038 and none, respectively. The fair market value adjustments were calculated utilizing the Black-Sholes method using the following assumptions: risk free rates ranging between 0.23% - 0.85%, dividend yield of 0%, expected life of 1 year, volatility between 256% - 375%. A summary of the activity of the derivative liability is shown below: Balance at December 31, 2014 - Derivative loss due to new issuances - Derivative loss due to mark to market adjustments - Balance at December 31, 2015 - Derivative loss due to new issuances (113,180 ) Derivative gain due to mark to market adjustment (66,858 ) Balance at December 31, 2016 (180,038 )

NOTE 7. INCOME TAXES

NOTE 7. INCOME TAXES	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
NOTE 7. INCOME TAXES	Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur. At December 31, 2015 and 2016 the Company had net operating loss carry forwards of approximately $7,048,000 and $7,299,000 respectively, that may be offset against future taxable income, if any, ratably through 2035. These carry-forwards are subject to review by the Internal Revenue Service. The deferred tax asset of at each date of $1,410,000 and $1,460,000 created by the net operating losses has been offset by a 100% valuation allowance because the likelihood of realization of the tax benefit cannot be determined. The change in the valuation allowance in 2015 and 2016 was $133,000 and $123,000. The effects of temporary differences that gives rise to significant portions of deferred tax assets at December 31, 2016 and 2015 are as follows: Dec. 31, Dec. 31, 2016 2015 Deferred tax asset Federal $ 1,095,000 $ 1,057,000 State 365,000 353,000 Valuation allowance (1,460,000 ) (1,410,000 ) Net deferred tax asset $ - $ - There is no current or deferred tax expense for the years ended December 31, 2016 and 2015. The Company has not filed tax returns however management believes there are no taxes due as of December 31, 2015 and 2016. There was no Federal income tax expense for the years ended December 31, 2016 and 2015 due to the Company’s net losses. For the years ended December 31, 2016 and 2015 state income tax expense was zero. The company includes interest and penalties arising from the underpayment of income taxes in the consolidated statements of operations in general and administrative expenses. The tax years that remain subject to examination by major taxing jurisdictions are those for the tax year of 2016, 2015, and 2014.

NOTE 8. STOCK OPTIONS AND SUBSC

NOTE 8. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
NOTE 8. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE	The Company accounts for employee and non-employee stock options under ASC 718 and ASC 505, whereby option costs are recorded based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Unless otherwise provided for, the Company covers option exercises by issuing new shares. The Company’s stock option activity is described below. Non-employee stock options At the beginning of 2012, the Company had 22,500 options outstanding for shares in Transbiotec - CA. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate of 2.67%, dividend yield of 0%, expected life of five years, volatility of 100%. During the year ended December 31, 2012 no options were exercised or expired, leaving a December 31, 2012 outstanding balance of 22,500 non-employee stock options, exercisable at prices from $0.10 - $0.15 per share with the option terms expiring from January 2012 through January 2015. All of these options are for the stock of TransBiotec - CA. During the year ended December 31, 2014, 20,000 options were exercised, leaving a December 31, 2014 outstanding balance of 2,500 non-employee stock options, exercisable at $0.10 per share with the option terms expiring in January 2015. During the year ended December 31, 2015, no options were exercised as all outstanding options expired in January 2015 leaving no outstanding balance of non-employee stock options in the stock of Transbiotec-CA at December 31, 2015. During the nine months ended September 30, 2016, no options were exercised as all outstanding options expired in January 2015 leaving no outstanding balance of non-employee stock options in the stock of Transbiotec-CA at September 30, 2016 During 2012 the Company granted 29,678 stock options, that were vested immediately, for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate of 0.8%, dividend yield of 0%, expected life of five years, volatility of 189%. No options were exercised or expired, leaving a December 31, 2012 outstanding balance of 29,678 options for Transbiotec - DE. The Company incurred and recorded compensation expense under these stock option grants of $4,042 in 2012. During 2013 the Company granted 5,321,735 stock options, that were vested immediately, for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rates between 7% - 14%, dividend yield of 0%, expected life of five years, volatility between 179% - 186%. No options were exercised or expired, leaving a December 31, 2013 outstanding balance of 5,351,413 options for Transbiotec - DE. The Company incurred and recorded compensation expense under these stock option grants of $145,997 in 2013. During 2014 the Company granted 8,403,633 stock options, that were vested immediately, for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rates between 1.55% - 1.77%, dividend yield of 0%, expected life of five years, volatility between 147% - 178%. No options were exercised or expired, leaving a December 31, 2014 outstanding balance of 13,755,046 options for Transbiotec - DE. The Company incurred and recorded compensation expense under these stock option grants of $69,886 in 2014. During the year ended December 31, 2015, the Company granted 16,282,995 stock options, that were vested immediately, for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate between 1.37% - 1.68%, dividend yield of 0%, expected life of five years, a volatility range of 172% - 174%. No options were exercised or expired, leaving a December 31, 2015 outstanding balance of 30,038,041 options for Transbiotec - DE. The Company incurred and recorded compensation expense under these stock option grants of $27,731 during the year ended December 31, 2015. During the year ended December 31, 2016, the Company granted 11,346,435 stock options, that were vested immediately, for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate between 1.03% - 1.30%, dividend yield of 0%, expected life of five years, a volatility rate between 162% - 167%. No options were exercised or expired, leaving a December 31, 2016 outstanding balance of 41,384,476 options for Transbiotec - DE. The Company incurred and recorded compensation expense under these stock option grants of $3,603 during the year ended December 31, 2016. A summary of stock option activity for California is as follows: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2015 - $ - Granted - - Exercised - - Forfeited - - Outstanding at December 31, 2016 - $ - A summary of stock option activity for Delaware is as follows: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2015 30,038,041 $ .0143 Granted 11,346,435 .0056 Exercised - - Forfeited - - Outstanding at September 30, 2016 41,384,476 $ .0119 Following is a summary of the status of options for Delaware outstanding at December 31, 2016: Exercise Price Number of Shares Remaining Contractual Life Weighted Average Exercise Price Exercised at December 31, 2016 $ 0.0900 29,678 2 years 0.0900 - $ 0.1700 83,333 3 years 0.1700 - $ 0.1700 27,778 3 years 0.1700 - $ 0.1700 362,624 3 years 0.1700 - $ 0.1300 80,914 3 years 0.1300 - $ 0.1300 429,086 3 years 0.1300 - $ 0.0600 38,000 3 years 0.0600 - $ 0.0400 250,000 3 years 0.0400 - $ 0.0400 1,625,000 3 years 0.0400 - $ 0.0500 400,000 3 years 0.0500 - $ 0.0400 75,000 3 years 0.0400 - $ 0.0400 300,000 3 years 0.0400 - $ 0.0200 300,000 3 years 0.0200 - $ 0.0200 1,200,000 3 years 0.0200 - $ 0.0400 150,000 3 years 0.0400 - $ 0.0125 1,200,000 4 years 0.0125 $ 0.0150 50,137 4 years 0.0150 - $ 0.0150 140,000 4 years 0.0150 - $ 0.0190 31,256 4 years 0.0190 - $ 0.0161 167,702 4 years 0.0161 - $ 0.0147 204,082 4 years 0.0147 - $ 0.0200 75,000 4 years 0.0200 - $ 0.0198 75,758 4 years 0.0198 - $ 0.0213 165,915 4 years 0.0213 - $ 0.0195 133,262 4 years 0.0195 - $ 0.0188 79,787 4 years 0.0188 - $ 0.0140 229,714 4 years 0.0140 - $ 0.0190 50,000 4 years 0.0190 - $ 0.0127 42,283 4 years 0.0127 - $ 0.0090 213,833 4 years 0.0090 - $ 0.0074 48,649 4 years 0.0074 - $ 0.0060 375,000 4 years 0.0060 - $ 0.0098 612,245 4 years 0.0098 - $ 0.0098 61,224 4 years 0.0098 - $ 0.2500 25,000 4 years 0.2500 - $ 0.0680 450,000 4 years 0.0680 - $ 0.0072 123,828 4 years 0.0072 - $ 0.0056 375,000 4 years 0.0056 - $ 0.0070 250,000 4 years 0.0070 - $ 0.0070 373,714 4 years 0.0070 - $ 0.0041 850,244 4 years 0.0041 - $ 0.0045 2,000,000 4 years 0.0045 - $ 0.0024 150,000 5 years 0.0024 - $ 0.0010 7,625,544 5 years 0.0010 - $ 0.0024 1,770,000 5 years 0.0024 - $ 0.0023 400,782 5 years 0.0023 - $ 0.0012 275,000 5 years 0.0012 - $ 0.0017 1,764,706 5 years 0.0017 - $ 0.0018 2,463,333 5 years 0.0018 - $ 0.0021 285,714 5 years 0.0021 - $ 0.0018 333,333 5 years 0.0018 - $ 0.0018 1,083,333 5 years 0.0018 - $ 0.0032 131,250 5 years 0.0032 - $ 0.0040 2,250,000 5 years 0.0040 - $ 0.0040 562,500 5 years 0.0040 - $ 0.0060 390,000 5 years 0.0060 - $ 0.0070 1,714,825 5 years 0.0070 - $ 0.0045 1,500,000 5 years 0.0045 - $ 0.0070 1,714,825 5 years 0.0070 - $ 0.0070 1,714,285 5 years 0.0070 - $ 0.0050 1,500,000 5 years 0.0050 - Total 41,384,476 0.0119 Employee stock options The parent company had no outstanding employee stock options. Stock subscriptions received At December 31, 2015 and December 31, 2016, the Company converted certain accounts payable into common shares which amounts to $55,868 for 6,049,578 common shares to be issued, and $28,067 for 87,084 common shares to be issued, respectively. At December 31, 2015 and December 31, 2016, the Company converted certain notes payable into preferred shares which amounts to $14 for 1,388,575 preferred shares to be issued, and $14 for 1,388,575, respectively.

NOTE 9. COMMON STOCK

NOTE 9. COMMON STOCK	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
NOTE 9. COMMON STOCK	On June 11, 2015, as an inducement for a loan, the Company issued 834,408 shares of its common stock on said date valued at $1,502 with a purchase price of $0.0018 per share. On August 20, 2015, the Company converted accrued interest of $3,900 into 1,000,000 shares of its common stock, with a purchase price $0.0039 per share. On January 21, 2016, the Company issued for $25,000 cash, 5,000,000 shares of its common stock, with a purchase price of $0.0050 per share. On January 21, 2016, the Company converted $9,750 of its account payable into 2,500,000 issued shares of its common stock, with a purchase price of $0.0039 per share.

NOTE 10. COMMITMENTS AND CONTIN

NOTE 10. COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
NOTE 10. COMMITMENTS AND CONTINGENCIES	Operating Leases The Company leases its office space under a long-term operating lease expiring in June 2019. Rent expense under this lease was $24,600 and $52,420 for the years ended December 31, 2015 and December 31, 2016, respectively. As of December 31, 2016, future minimum annual payments under operating lease agreements for years ending December 31 are as follows. 2017 2018 2019 2020 2021 Total Operating leases 49,200 49,200 24,600 - - 123,000 $ 49,200 $ 49,200 $ 24,600 $ - $ - $ 123,000

NOTE 1. ORGANIZATION, OPERATI17

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2016
Note 1. Organization Operations And Summary Of Significant Accounting Policies Policies
Basis of Presentation	The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) as promulgated in the United States of America.
Principles of Consolidation	The accompanying consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Transbiotec-CA. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Specifically, such estimates were made by the Company for the valuation of derivative liability, stock compensation and beneficial conversion feature expenses. Actual results could differ from those estimates.
Cash	The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents. The Company does not have any cash equivalents as of December 31, 2016 and December 31, 2015.
Property and equipment	Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life.
Income tax	The Company accounts for income taxes pursuant to ASC 740. Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Net loss per share	The net loss per share is computed by dividing the net loss by the weighted average number of shares of common outstanding. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations. The Company has 41,384,476 stock options that can be converted to common stock if exercised.
Financial Instruments	Pursuant to ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets: quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist primarily of cash, accounts payable, accrued expenses, notes payable, related party payables, convertible debentures, and other payable. Pursuant to ASC 820 and 825, the fair value of our cash and cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2016 and 2015 on a recurring basis: December 31, 2015 Level 1 Level 2 Level 3 $ $ $ - - - - - - December 31, 2016 Level 1 Level 2 Level 3 $ $ $ Derivative liabilities (180,038 ) - - (180,038 ) - -
Long-Lived Assets	In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that may suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value.
Beneficial Conversion Features	From time to time, the Company may issue convertible notes that may contain an embedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.
Derivative Instruments	The fair value of derivative instruments is recorded and shown separately under current liabilities. Changes in fair value are recorded in the consolidated statement of income under other income (expenses). The accounting treatment of derivative financial instruments requires that the Company record the embedded conversion option and warrants at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. As a result of entering into warrant agreements, for which such instruments contained a variable conversion feature with no floor, the Company has adopted a sequencing policy in accordance with ASC 815-40-35-12 whereby all future instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instruments are initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a weighted average Black-Sholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
Stock based compensation	The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options and warrants to purchase shares of Company common stock at the fair market value at the time of the grant. Stock-based compensation cost to employees is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period under ASC718. For options issued to employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. Grants of stock to non-employees and other parties are accounted for in accordance with the ASC 505.
Recent accounting pronouncement	In August 2014, the FASB issued the FASB Accounting Standards Update No. 2014-15 “Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). In connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). The term probable is used consistently with its use in Topic 450, Contingencies. When management identifies conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern, management should consider whether its plans that are intended to mitigate those relevant conditions or events will alleviate the substantial doubt. The mitigating effect of management’s plans should be considered only to the extent that (1) it is probable that the plans will be effectively implemented and, if so, (2) it is probable that the plans will mitigate the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. If conditions or events raise substantial doubt about an entity’s ability to continue as a going concern, but the substantial doubt is alleviated as a result of consideration of management’s plans, the entity should disclose information that enables users of the financial statements to understand all of the following (or refer to similar information disclosed elsewhere in the footnotes): a. Principal conditions or events that raised substantial doubt about the entity’s ability to continue as a going concern (before consideration of management’s plans). b. Management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations. c. Management’s plans that alleviated substantial doubt about the entity’s ability to continue as a going concern. If conditions or events raise substantial doubt about an entity’s ability to continue as a going concern, but the substantial doubt is not alleviated after consideration of management’s plans, an entity should include a statement in the footnotes indicating that there is substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or available to be issued). Additionally, the entity should disclose information that enables users of the financial statements to understand all of the following: a. Principal conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. b. Management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations. b. Management’s plans that are intended to mitigate the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for the annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact of the adoptions of ASU 2014-15 on its consolidated financial statements.
Minority Interest (Noncontrolling Interest)	A subsidiary of the Company has minority members, representing ownership interests of 1.38% at December 31, 2016. The Company accounts for these minority, or noncontrolling interests pursuant to ASC 810-10-65 whereby gains and losses in a subsidiary with a noncontrolling interest are allocated to the noncontrolling interest based on the ownership percentage of the noncontrolling interest, even if that allocation results in a deficit noncontrolling interest balance.

NOTE 1. ORGANIZATION, OPERATI18

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2016
Note 1. Organization Operations And Summary Of Significant Accounting Policies Tables
Fair value Assets and Liabilities	The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2016 and 2015 on a recurring basis: December 31, 2015 Level 1 Level 2 Level 3 $ $ $ - - - - - - December 31, 2016 Level 1 Level 2 Level 3 $ $ $ Derivative liabilities (180,038 ) - - (180,038 ) - -

NOTE 4. PROPERTY & EQUIPMENT (T

NOTE 4. PROPERTY & EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Note 4. Property Equipment Tables
Fixed asset values	Property and equipment values recorded at cost are as follows: Dec. 31, 2016 Dec. 31, 2015 Office and Lab Equipment $ 32,127 $ 32,127 Furniture and fixtures 11,556 11,556 43,683 43,683 Less accumulated depreciation (43,683 ) (43,683 ) Property & Equipment, Net $ - $ -

NOTE 5. NOTES PAYABLE (Tables)

NOTE 5. NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2016
Note 5. Notes Payable Tables
Notes Payables	December 31, 2016 December 31, 2015 Note payable to related party, unsecured, due 8/3/2012, interest rate 0%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 1,950 $ 1,950 Notes payable to related party, unsecured, due 12/31/2012, interest rate 0%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 11,810 $ 11,810 Note payable to related party, unsecured, $731,763, 5-years at 0% simple interest, due 7/1/2016, payment amounts vary each month, various late penalties. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 180,001 $ 180,001 Note payable to non-related party, unsecured, due 2/8/12, quarterly interest due, convertible at holder’s option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 10,000 $ 10,000 Note payable to non-related party, unsecured, due 11/8/12, quarterly interest due, convertible at holder’s option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 25,000 $ 25,000 Note payable to non-related party, unsecured, due 2/17/12, quarterly interest due, convertible at holder’s option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 25,000 $ 25,000 Note payable to non-related party, unsecured, due 2/18/12, quarterly interest due, convertible at holder’s option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 10,000 $ 10,000 Note payable to non-related party, unsecured, due 2/8/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 18%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 750 $ 750 Note payable to non-related party, unsecured, due 2/8/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 18%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 6,875 $ 6,875 Note payable to non-related party, unsecured, due 2/15/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 2,500 $ 2,500 Note payable to non-related party, unsecured, due 2/20/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 3,750 $ 3,750 Note payable to non-related party, unsecured, due 2/21/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE. share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 2,625 $ 2,625 Note payable to non-related party, unsecured, due 3/20/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 5,433 $ 5,433 Note payable to non-related party, unsecured, due 3/22/13, annual interest due, convertible at holder’s option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 3,203 $ 3,203 Note payable to non-related party, unsecured, due 08/29/2013, simple interest 8% convertible at holder’s option at $.249 per TBT-CA share. Currently in default. Principal balance including interest to be paid upon receipt of equity funding and/or sales revenue. $ 15,000 $ 15,000 Note payable to related party, unsecured, due 03/01/2013, simple interest 9%. Currently in default. Principal balance including interest to be paid upon receipt of equity funding and/or sales revenue. $ 5,000 $ 5,000 Note payable to non-related party, unsecured, due 01/31/2013, simple interest 18%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 3,938 $ 3,938 Note payable to related party, unsecured, due 01/23/2014, simple interest 9% convertible at holder’s option at $.08 per TBT-DE share Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 50,000 $ 50,000 Note payable to related party, unsecured, due 07/02/2014, simple interest 9% convertible at holder’s option at $.04 per TBT-DE share Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 15,000 $ 15,000 Note payable to non-related party, unsecured, due 10/25/2013, simple interest 18% convertible at holder’s option at $.016 per TBT-DE share Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 2,000 $ 2,000 Note payable to non-related party, unsecured, due 12/27/2013, simple interest 9% quarterly, Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 15,000 $ 15,000 Note payable to non-related party, unsecured, due 9/11/2014, simple interest 10% yearly. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 5,000 $ 5,000 Note payable to related party, unsecured, due 11/12/2014, simple interest 9% convertible at holder’s option at $0.04 per TBT-DE share, currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 11,000 $ 11,000 Note payable to related party, unsecured, due 4/08/2015, simple interest 7% convertible at holder’s option at $0.0072 per TBT-DE share. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 15,000 $ 15,000 Note payable to related party, unsecured, due 8/05/2015, simple interest 7%, default interest 10%. Currently in default. Note contains a stock option. $ 10,000 $ 10,000 Note payable to related party unsecured, due 12/02/2015, simple interest 7%, default interest 10%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 106,334 $ 106,334 Note payable to non-related party, unsecured, due 3/26/2016, simple interest 8%, convertible at holder’s option at $0.0017 per TBT-DE share. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 25,000 $ 25,000 Note payable to related party, unsecured, due 4/11/2016, simple interest 10%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 13,000 $ 13,000 Note payable to related party, unsecured, due 11/11/2015, simple interest 10%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 45,000 $ 45,000 Note payable to non-related party, unsecured, due 11/11/2015, simple interest 10%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 2,500 $ 2,500 Note payable to related party, unsecured, due 12/26/2015, simple interest 10%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 25,000 $ 25,000 Note payable to related party, unsecured, due on demand, simple interest 10%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 15,277 $ - Note payable to related party, unsecured, due 7/23/2016, simple interest 10%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 15,000 $ - Note payable to related party, unsecured, due 5/1/2017, simple interest 7%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 3,750 $ - Note payable to related party, unsecured, due 11/9/2016, simple interest 7%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 15,000 $ - Note payable to related party, unsecured, due 7/26/2017, simple interest 7%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 3,900 $ - Note payable to related party, unsecured, due 8/03/2017, simple interest 7%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 20,000 $ - Note payable to related party, unsecured, due 9/28/2017, simple interest 7%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 20,000 $ - Note payable to related party, unsecured, due 10/05/2017, simple interest 7%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 20,000 $ - Note payable to related party, unsecured, due 11/15/2017, simple interest 7%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note contains a stock option. $ 25,000 $ - $ 790,596 $ 652,669 Less note discounts - (5,000 ) Less current - related parties (627,022 ) (489,095 ) Less current - non-related parties (163,574 ) (157,324 ) Long-term - related parties $ - $ -
Principal payments	Required principal payments from December 31, 2016 forward are as follows: 2017 $ 790,596 2018 $ - 2019 $ - 2020 $ - 2021 $ - $ 790,596

NOTE 6. DERIVATIVE LIABILITY (T

NOTE 6. DERIVATIVE LIABILITY (Tables)	12 Months Ended
	Dec. 31, 2016
Note 6. Derivative Liability Tables
Summary of the Activity of the Derivative Liability	A summary of the activity of the derivative liability is shown below: Balance at December 31, 2014 - Derivative loss due to new issuances - Derivative loss due to mark to market adjustments - Balance at December 31, 2015 - Derivative loss due to new issuances (113,180 ) Derivative gain due to mark to market adjustment (66,858 ) Balance at December 31, 2016 (180,038 )

NOTE 7. INCOME TAXES (Tables)

NOTE 7. INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2016
Note 7. Income Taxes Tables
Summary of deferred tax assets	The effects of temporary differences that gives rise to significant portions of deferred tax assets at December 31, 2016 and 2015 are as follows: Dec. 31, Dec. 31, 2016 2015 Deferred tax asset Federal $ 1,095,000 $ 1,057,000 State 365,000 353,000 Valuation allowance (1,460,000 ) (1,410,000 ) Net deferred tax asset $ - $ -

NOTE 8. STOCK OPTIONS AND SUB23

NOTE 8. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2016
Note 8. Stock Options And Subscriptions Payable Tables
Summary of stock option activity for California	A summary of stock option activity for California is as follows: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2015 - $ - Granted - - Exercised - - Forfeited - - Outstanding at December 31, 2016 - $ -
Summary of stock option activity for Delaware	A summary of stock option activity for Delaware is as follows: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2015 30,038,041 $ .0143 Granted 11,346,435 .0056 Exercised - - Forfeited - - Outstanding at September 30, 2016 41,384,476 $ .0119
Schedule of common stock options and warrants Delaware outstanding	Following is a summary of the status of options for Delaware outstanding at December 31, 2016: Exercise Price Number of Shares Remaining Contractual Life Weighted Average Exercise Price Exercised at December 31, 2016 $ 0.0900 29,678 2 years 0.0900 - $ 0.1700 83,333 3 years 0.1700 - $ 0.1700 27,778 3 years 0.1700 - $ 0.1700 362,624 3 years 0.1700 - $ 0.1300 80,914 3 years 0.1300 - $ 0.1300 429,086 3 years 0.1300 - $ 0.0600 38,000 3 years 0.0600 - $ 0.0400 250,000 3 years 0.0400 - $ 0.0400 1,625,000 3 years 0.0400 - $ 0.0500 400,000 3 years 0.0500 - $ 0.0400 75,000 3 years 0.0400 - $ 0.0400 300,000 3 years 0.0400 - $ 0.0200 300,000 3 years 0.0200 - $ 0.0200 1,200,000 3 years 0.0200 - $ 0.0400 150,000 3 years 0.0400 - $ 0.0125 1,200,000 4 years 0.0125 $ 0.0150 50,137 4 years 0.0150 - $ 0.0150 140,000 4 years 0.0150 - $ 0.0190 31,256 4 years 0.0190 - $ 0.0161 167,702 4 years 0.0161 - $ 0.0147 204,082 4 years 0.0147 - $ 0.0200 75,000 4 years 0.0200 - $ 0.0198 75,758 4 years 0.0198 - $ 0.0213 165,915 4 years 0.0213 - $ 0.0195 133,262 4 years 0.0195 - $ 0.0188 79,787 4 years 0.0188 - $ 0.0140 229,714 4 years 0.0140 - $ 0.0190 50,000 4 years 0.0190 - $ 0.0127 42,283 4 years 0.0127 - $ 0.0090 213,833 4 years 0.0090 - $ 0.0074 48,649 4 years 0.0074 - $ 0.0060 375,000 4 years 0.0060 - $ 0.0098 612,245 4 years 0.0098 - $ 0.0098 61,224 4 years 0.0098 - $ 0.2500 25,000 4 years 0.2500 - $ 0.0680 450,000 4 years 0.0680 - $ 0.0072 123,828 4 years 0.0072 - $ 0.0056 375,000 4 years 0.0056 - $ 0.0070 250,000 4 years 0.0070 - $ 0.0070 373,714 4 years 0.0070 - $ 0.0041 850,244 4 years 0.0041 - $ 0.0045 2,000,000 4 years 0.0045 - $ 0.0024 150,000 5 years 0.0024 - $ 0.0010 7,625,544 5 years 0.0010 - $ 0.0024 1,770,000 5 years 0.0024 - $ 0.0023 400,782 5 years 0.0023 - $ 0.0012 275,000 5 years 0.0012 - $ 0.0017 1,764,706 5 years 0.0017 - $ 0.0018 2,463,333 5 years 0.0018 - $ 0.0021 285,714 5 years 0.0021 - $ 0.0018 333,333 5 years 0.0018 - $ 0.0018 1,083,333 5 years 0.0018 - $ 0.0032 131,250 5 years 0.0032 - $ 0.0040 2,250,000 5 years 0.0040 - $ 0.0040 562,500 5 years 0.0040 - $ 0.0060 390,000 5 years 0.0060 - $ 0.0070 1,714,825 5 years 0.0070 - $ 0.0045 1,500,000 5 years 0.0045 - $ 0.0070 1,714,825 5 years 0.0070 - $ 0.0070 1,714,285 5 years 0.0070 - $ 0.0050 1,500,000 5 years 0.0050 - Total 41,384,476 0.0119

NOTE 10. COMMITMENTS AND CONT24

NOTE 10. COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2016
Note 10. Commitments And Contingencies Tables
Schedule of future minimum annual payments	As of December 31, 2016, future minimum annual payments under operating lease agreements for years ending December 31 are as follows. 2017 2018 2019 2020 2021 Total Operating leases 49,200 49,200 24,600 - - 123,000 $ 49,200 $ 49,200 $ 24,600 $ - $ - $ 123,000

NOTE 1. ORGANIZATION, OPERATI25

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Fair value of assets and liabilities on recurring basis	$ (180,038)
Level 1 [Member]
Fair value of assets and liabilities on recurring basis	(180,038)
Level 2 [Member]
Fair value of assets and liabilities on recurring basis
Level 3 [Member]
Fair value of assets and liabilities on recurring basis

NOTE 1. ORGANIZATION, OPERATI26

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	12 Months Ended
	Dec. 31, 2016shares
Note 1. Organization Operations And Summary Of Significant Accounting Policies Details Narrative
Ownership interests	1.38%
Entity Incorporation, State Country Name	State of Delaware
Entity Incorporation, Date of Incorporation	Aug. 31, 2007
Stock options	41,384,476

NOTE 2. GOING CONCERN (Details

NOTE 2. GOING CONCERN (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Note 2. Going Concern Details Narrative
Accumulated deficit	$ (17,064,086)	$ (16,468,956)

NOTE 3. RELATED PARTY TRANSAC28

NOTE 3. RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Dec. 03, 2014	Dec. 31, 2016	Dec. 31, 2015	Jul. 01, 2015	Dec. 31, 2014
Payables due to officers, shareholders and former management		$ 1,111,754	$ 412,656
Outstanding accounts payable conversion percentage into common stock	50.00%
Common stock conversion price	$ .09
Convertible accounts payable		$ 61,009	$ 86,624		$ 103,395
Converted shares		677,871	962,494
Rent expense		$ 52,420	$ 24,600
Lanphere Law Group [Member]
Debt amount				$ 214,335
Debt forgiven				108,000
Debt amount after debt forgiveness				$ 106,335
Lease monthly rent		$ 4,100

NOTE 4. PROPERTY & EQUIPMENT (D

NOTE 4. PROPERTY & EQUIPMENT (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Note 4. Property Equipment Details
Office and Lab Equipment	$ 32,127	$ 32,127
Furniture and fixtures	11,556	11,556
Gross Fixed Assets	43,683	43,683
Less accumulated depreciation	(43,683)	(43,683)
Property & Equipment, Net

NOTE 4. PROPERTY & EQUIPMENT 30

NOTE 4. PROPERTY & EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Note 4. Property Equipment Details Narrative
Depreciation expense	$ 0	$ 454

NOTE 5. NOTES PAYABLE (Details)

NOTE 5. NOTES PAYABLE (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Notes Payable	$ 790,596	$ 652,669
Less note discounts		(5,000)
Less current - related parties	(627,022)	(489,095)
Less current non-related parties	(163,574)	(157,324)
Long-term related parties
Note payable 1 [Member]
Notes Payable	1,950	1,950
Note payable 2 [Member]
Notes Payable	11,810	11,810
Note payable 3 [Member]
Notes Payable	180,001	180,001
Note payable 4 [Member]
Notes Payable	10,000	10,000
Note payable 5 [Member]
Notes Payable	25,000	25,000
Note payable 6 [Member]
Notes Payable	25,000	25,000
Note payable 7 [Member]
Notes Payable	10,000	10,000
Note payable 8 [Member]
Notes Payable	750	750
Note payable 9 [Member]
Notes Payable	6,875	6,875
Note payable 10 [Member]
Notes Payable	2,500	2,500
Note payable 11 [Member]
Notes Payable	3,750	3,750
Note payable 12 [Member]
Notes Payable	2,625	2,625
Note payable 13 [Member]
Notes Payable	5,433	5,433
Note payable 14 [Member]
Notes Payable	3,203	3,203
Note payable 15 [Member]
Notes Payable	15,000	15,000
Note payable 16 [Member]
Notes Payable	5,000	5,000
Note payable 17 [Member]
Notes Payable	3,938	3,938
Note payable 18 [Member]
Notes Payable	50,000	50,000
Note payable 19 [Member]
Notes Payable	15,000	15,000
Note payable 20 [Member]
Notes Payable	2,000	2,000
Note payable 21 [Member]
Notes Payable	15,000	15,000
Note payable 22 [Member]
Notes Payable	5,000	5,000
Note payable 23 [Member]
Notes Payable	11,000	11,000
Note payable 24 [Member]
Notes Payable	15,000	15,000
Note payable 25 [Member]
Notes Payable	10,000	10,000
Note payable 26 [Member]
Notes Payable	106,334	106,334
Note payable 27 [Member]
Notes Payable	25,000	25,000
Note payable 28 [Member]
Notes Payable	13,000	13,000
Note payable 29 [Member]
Notes Payable	45,000	45,000
Note payable 30 [Member]
Notes Payable	2,500	2,500
Note payable 31 [Member]
Notes Payable	25,000	25,000
Note payable 32 [Member]
Notes Payable	15,277
Note payable 33 [Member]
Notes Payable	15,000
Note payable 34 [Member]
Notes Payable	3,750
Note payable 35 [Member]
Notes Payable	15,000
Note payable 36 [Member]
Notes Payable	3,900
Note payable 37 [Member]
Notes Payable	20,000
Note payable 38 [Member]
Notes Payable	20,000
Note payable 39 [Member]
Notes Payable	20,000
Note payable 40 [Member]
Notes Payable	$ 25,000

NOTE 5. NOTES PAYABLE (Details

NOTE 5. NOTES PAYABLE (Details 1)	Dec. 31, 2016USD ($)
Note 5. Notes Payable Details 1
2,017	$ 790,596
2,018
2,019
2,020
2,021
Total principal payment	$ 790,596

NOTE 5. NOTES PAYABLE (Detail33

NOTE 5. NOTES PAYABLE (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2012	Dec. 31, 2014
Interest expense	$ 121,338	$ 198,327
Beneficial Conversion Feature Interest Expense	(15,250)	23,750
Borrowing under convertible notes			$ 110,000
Convertible Notes	61,009	86,624		$ 103,395
Fair value adjustments - equity obligation	$ 0	(25,456)
Dividend yield	0.00%
Expected life	1 year
Fair value derivative liability	$ (180,038)
Note payable 1 [Member]
Note payable due date	Aug. 3, 2012	Aug. 3, 2012
Interest rate	0.00%	0.00%
Note payable 2 [Member]
Note payable due date	Dec. 31, 2012	Dec. 31, 2012
Interest rate	0.00%	0.00%
Note payable 3 [Member]
Note payable due date	Jul. 1, 2016	Jul. 1, 2016
Interest rate	0.00%	0.00%
Maturity term	5 years	5 years
Note payable unsecured amount	$ 731,763	$ 731,763
Note payable 4 [Member]
Note payable due date	Feb. 8, 2012	Feb. 8, 2012
Interest rate	30.00%	30.00%
Note payable conversion price per share	$ 0.3235688	$ 0.3235688
Note payable 5 [Member]
Note payable due date	Nov. 8, 2012	Nov. 8, 2012
Interest rate	30.00%	30.00%
Note payable conversion price per share	$ 0.3235688	$ 0.3235688
Note payable 6 [Member]
Note payable due date	Feb. 17, 2012	Feb. 17, 2012
Interest rate	30.00%	30.00%
Note payable conversion price per share	$ 0.3235688	$ 0.3235688
Note payable 7 [Member]
Note payable due date	Feb. 18, 2012	Feb. 18, 2012
Interest rate	30.00%	30.00%
Note payable conversion price per share	$ 0.3235688	$ 0.3235688
Note payable 8 [Member]
Note payable due date	Feb. 8, 2013	Feb. 8, 2013
Interest rate	18.00%	18.00%
Note payable conversion price per share	$ 0.3235688	$ 0.3235688
Note payable 9 [Member]
Note payable due date	Feb. 8, 2013	Feb. 8, 2013
Interest rate	18.00%	18.00%
Note payable conversion price per share	$ 0.3235688	$ 0.3235688
Note payable 10 [Member]
Note payable due date	Feb. 15, 2013	Feb. 15, 2013
Interest rate	12.00%	12.00%
Note payable conversion price per share	$ 0.3235688	$ 0.3235688
Note payable 11 [Member]
Note payable due date	Feb. 20, 2013	Feb. 20, 2013
Interest rate	12.00%	12.00%
Note payable conversion price per share	$ 0.3235688	$ 0.3235688
Note payable 12 [Member]
Note payable due date	Feb. 21, 2013	Feb. 21, 2013
Interest rate	12.00%	12.00%
Note payable conversion price per share	$ 0.3235688	$ 0.3235688
Note payable 13 [Member]
Note payable due date	Mar. 20, 2013	Mar. 20, 2013
Interest rate	12.00%	12.00%
Note payable conversion price per share	$ 0.3235688	$ 0.3235688
Note payable 14 [Member]
Note payable due date	Mar. 22, 2013	Mar. 22, 2013
Interest rate	12.00%	12.00%
Note payable conversion price per share	$ 0.3235688	$ 0.3235688
Note payable 15 [Member]
Note payable due date	Aug. 29, 2013	Aug. 29, 2013
Interest rate	8.00%	8.00%
Note payable conversion price per share	$ .249	$ 0.249
Note payable 16 [Member]
Note payable due date	Mar. 1, 2013	Mar. 1, 2013
Interest rate	9.00%	9.00%
Note payable 17 [Member]
Note payable due date	Jan. 31, 2013	Jan. 31, 2013
Interest rate	18.00%	18.00%
Note payable 18 [Member]
Note payable due date	Jan. 23, 2014	Jan. 23, 2014
Interest rate	9.00%	9.00%
Note payable conversion price per share	$ .08	$ 0.08
Note payable 19 [Member]
Note payable due date	Jul. 2, 2014	Jul. 2, 2014
Interest rate	9.00%	9.00%
Note payable conversion price per share	$ .04	$ 0.04
Note payable 20 [Member]
Note payable due date	Oct. 25, 2013	Oct. 25, 2013
Interest rate	18.00%	18.00%
Note payable conversion price per share	$ .016	$ 0.016
Note payable 21 [Member]
Note payable due date	Dec. 27, 2013	Dec. 27, 2013
Interest rate	9.00%	9.00%
Note payable 22 [Member]
Note payable due date	Sep. 11, 2014	Sep. 11, 2014
Interest rate	10.00%	10.00%
Note payable 23 [Member]
Note payable due date	Nov. 12, 2014	Nov. 12, 2014
Interest rate	9.00%	9.00%
Note payable conversion price per share	$ 0.04	$ 0.04
Note payable 24 [Member]
Note payable due date	Apr. 8, 2015	Apr. 8, 2015
Interest rate	7.00%	7.00%
Note payable conversion price per share	$ 0.0072	$ 0.0072
Note payable 25 [Member]
Note payable due date	Aug. 5, 2015	Aug. 5, 2015
Interest rate	7.00%	7.00%
Default interest rate	10.00%	10.00%
Note payable 26 [Member]
Note payable due date	Dec. 2, 2015	Dec. 2, 2015
Interest rate	7.00%	7.00%
Default interest rate	10.00%	10.00%
Note payable 27 [Member]
Note payable due date	Mar. 26, 2016	Mar. 26, 2016
Interest rate	8.00%	8.00%
Note payable conversion price per share	$ 0.0017	$ 0.0017
Note payable 28 [Member]
Note payable due date	Apr. 11, 2016	Apr. 11, 2016
Interest rate	10.00%	10.00%
Note payable 29 [Member]
Note payable due date	Nov. 11, 2015	Nov. 11, 2015
Interest rate	10.00%	10.00%
Note payable 30 [Member]
Note payable due date	Nov. 11, 2015	Nov. 11, 2015
Interest rate	10.00%	10.00%
Note payable 31 [Member]
Note payable due date	Dec. 26, 2015	Dec. 26, 2015
Interest rate	10.00%	10.00%
Note payable 32 [Member]
Interest rate	10.00%	10.00%
Note payable 33 [Member]
Note payable due date	Jul. 23, 2016	Jul. 23, 2016
Interest rate	10.00%	10.00%
Note payable 34 [Member]
Note payable due date	May 1, 2017	May 1, 2017
Interest rate	7.00%	7.00%
Note payable 35 [Member]
Note payable due date	Nov. 9, 2016	Nov. 9, 2016
Interest rate	7.00%	7.00%
Note payable 36 [Member]
Note payable due date	Jul. 26, 2017	Jul. 26, 2017
Interest rate	7.00%	7.00%
Note payable 37 [Member]
Note payable due date	Aug. 3, 2017	Aug. 3, 2017
Interest rate	7.00%	7.00%
Note payable 38 [Member]
Note payable due date	Sep. 28, 2017	Sep. 28, 2017
Interest rate	7.00%	7.00%
Note payable 39 [Member]
Note payable due date	Oct. 5, 2017	Oct. 5, 2017
Interest rate	7.00%	7.00%
Note payable 40 [Member]
Note payable due date	Nov. 15, 2017	Nov. 15, 2017
Interest rate	7.00%	7.00%
Minimum [Member]
Risk free interest rate	0.23%
Volatility	256.00%
Minimum [Member] | Note Payable [Member]
Risk free interest rate	0.10%
Volatility	128.00%
Maximum [Member]
Risk free interest rate	0.85%
Volatility	375.00%
Maximum [Member] | Note Payable [Member]
Risk free interest rate	0.21%
Volatility	354.00%

NOTE 6. DERIVATIVE LIABILITY (D

NOTE 6. DERIVATIVE LIABILITY (Details ) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Note 6. Derivative Liability Details
Begnning balance
Derivative loss due to new issuances	(113,180)
Derivative loss due to mark to market adjustments	(66,858)
Ending Balance	$ 180,038

NOTE 6. DERIVATIVE LIABILITY 35

NOTE 6. DERIVATIVE LIABILITY (Details Narrative ) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Stock options granted	15,643,398
Note convert into common shares	15,646,982
Common stock shares authorized	100,000,000	100,000,000
Fair market value adjustments related to stock options	$ 180,038
Dividend yield	0.00%
Expected life	1 year
Minimum [Member]
Risk free interest rates	0.23%
Volatility	256.00%
Maximum [Member]
Risk free interest rates	0.85%
Volatility	375.00%

NOTE 7. INCOME TAXES (Details)

NOTE 7. INCOME TAXES (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax asset
Federal	$ 1,095,000	$ 1,057,000
State	365,000	353,000
Valuation allowance	(1,460,000)	(1,410,000)
Net deferred tax asset

NOTE 7. INCOME TAXES (Details N

NOTE 7. INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Note 7. Income Taxes Details Narrative
Net operating loss carry forwards	$ 7,299,000	$ 7,048,000
Carryforward expiration year	2,035
Deferred tax asset	$ 1,460,000	$ 1,410,000
Rate of net operating losses offset by valuation allowance	100.00%	100.00%
Change in the valuation allowance	$ 123,000	$ 133,000

NOTE 8. STOCK OPTIONS AND SUB38

NOTE 8. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE (Details)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Number of Shares
Granted | shares	15,643,398
Weighted Average Exercise Price
Outstanding at end of period | $ / shares	$ 0.0119
California
Number of Shares
Outstanding at beginning of period | shares
Granted | shares
Exercised | shares
Forfeited | shares
Outstanding at end of period | shares
Weighted Average Exercise Price
Outstanding at beginning of period | $ / shares
Granted | $ / shares
Exercised | $ / shares
Forfeited | $ / shares
Outstanding at end of period | $ / shares
Delaware
Number of Shares
Outstanding at beginning of period | shares	30,038,041
Granted | shares	11,346,435
Exercised | shares
Forfeited | shares
Outstanding at end of period | shares	41,384,476
Weighted Average Exercise Price
Outstanding at beginning of period | $ / shares	$ 0.0143
Granted | $ / shares	.0056
Exercised | $ / shares
Forfeited | $ / shares
Outstanding at end of period | $ / shares	$ .0119

NOTE 8. STOCK OPTIONS AND SUB39

NOTE 8. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE (Details 1)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Number of Shares | shares	41,384,476
Weighted Average Exercise Price	$ 0.0119
0.0900 Delaware
Exercise Price	$ 0.09
Number of Shares | shares	29,678
Weighted Average Remaining Contractual Life (Years)	2 years
Weighted Average Exercise Price	$ 0.09
Exercised at December 31, 2014 | shares
0.1700 Delaware
Exercise Price	$ 0.17
Number of Shares | shares	83,333
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.17
Exercised at December 31, 2014 | shares
0.1700 Delaware
Exercise Price	$ 0.17
Number of Shares | shares	27,778
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.17
Exercised at December 31, 2014 | shares
0.1700 Delaware
Exercise Price	$ 0.17
Number of Shares | shares	362,624
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.17
Exercised at December 31, 2014 | shares
0.1300 Delaware
Exercise Price	$ 0.13
Number of Shares | shares	80,914
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.13
Exercised at December 31, 2014 | shares
0.1300 Delaware
Exercise Price	$ 0.13
Number of Shares | shares	429,086
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.13
Exercised at December 31, 2014 | shares
0.0600 Delaware
Exercise Price	$ 0.06
Number of Shares | shares	38,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.06
Exercised at December 31, 2014 | shares
0.0400 Delaware
Exercise Price	$ 0.04
Number of Shares | shares	250,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.04
Exercised at December 31, 2014 | shares
0.0400 Delaware
Exercise Price	$ 0.04
Number of Shares | shares	1,625,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.04
Exercised at December 31, 2014 | shares
0.0500 Delaware
Exercise Price	$ 0.05
Number of Shares | shares	400,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.05
Exercised at December 31, 2014 | shares
0.0400 Delaware
Exercise Price	$ 0.04
Number of Shares | shares	75,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.04
Exercised at December 31, 2014 | shares
0.0400 Delaware
Exercise Price	$ 0.04
Number of Shares | shares	300,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.04
Exercised at December 31, 2014 | shares
0.0200 Delaware
Exercise Price	$ 0.02
Number of Shares | shares	300,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.02
Exercised at December 31, 2014 | shares
0.0200 Delaware
Exercise Price	$ 0.02
Number of Shares | shares	1,200,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.02
Exercised at December 31, 2014 | shares
0.0400 Delaware
Exercise Price	$ 0.04
Number of Shares | shares	150,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.04
Exercised at December 31, 2014 | shares
0.0125 Delaware
Exercise Price	$ 0.0125
Number of Shares | shares	1,200,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0125
0.0150 Delaware
Exercise Price	$ 0.015
Number of Shares | shares	50,137
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.015
Exercised at December 31, 2014 | shares
0.0150 Delaware
Exercise Price	$ 0.015
Number of Shares | shares	140,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.015
Exercised at December 31, 2014 | shares
0.0190 Delaware
Exercise Price	$ 0.019
Number of Shares | shares	31,256
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.019
Exercised at December 31, 2014 | shares
0.0161 Delaware
Exercise Price	$ 0.0161
Number of Shares | shares	167,702
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0161
Exercised at December 31, 2014 | shares
0.0147 Delaware
Exercise Price	$ 0.0147
Number of Shares | shares	204,082
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0147
Exercised at December 31, 2014 | shares
0.0200 Delaware
Exercise Price	$ 0.02
Number of Shares | shares	75,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.02
0.0198 Delaware
Exercise Price	$ 0.0198
Number of Shares | shares	75,758
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0198
Exercised at December 31, 2014 | shares
0.0213 Delaware
Exercise Price	$ 0.0213
Number of Shares | shares	165,915
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0213
Exercised at December 31, 2014 | shares
0.0195 Delaware
Exercise Price	$ 0.0195
Number of Shares | shares	133,262
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0195
Exercised at December 31, 2014 | shares
0.0188 Delaware
Exercise Price	$ 0.0188
Number of Shares | shares	79,787
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0188
Exercised at December 31, 2014 | shares
0.0140 Delaware
Exercise Price	$ 0.014
Number of Shares | shares	229,714
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.014
Exercised at December 31, 2014 | shares
0.0190 Delaware
Exercise Price	$ 0.019
Number of Shares | shares	50,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.019
Exercised at December 31, 2014 | shares
0.0127 Delaware
Exercise Price	$ 0.0127
Number of Shares | shares	42,283
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0127
Exercised at December 31, 2014 | shares
0.0090 Delaware
Exercise Price	$ 0.009
Number of Shares | shares	213,833
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.009
Exercised at December 31, 2014 | shares
0.0074 Delaware
Exercise Price	$ 0.0074
Number of Shares | shares	48,649
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0074
Exercised at December 31, 2014 | shares
0.0060 Delaware
Exercise Price	$ 0.006
Number of Shares | shares	375,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.006
Exercised at December 31, 2014 | shares
0.0098 Delaware
Exercise Price	$ 0.0098
Number of Shares | shares	612,245
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0098
Exercised at December 31, 2014 | shares
0.0098 Delaware
Exercise Price	$ 0.0098
Number of Shares | shares	61,224
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0098
Exercised at December 31, 2014 | shares
0.2500 Delaware
Exercise Price	$ 0.25
Number of Shares | shares	25,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.25
Exercised at December 31, 2014 | shares
0.0680 Delaware
Exercise Price	$ 0.068
Number of Shares | shares	450,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.068
Exercised at December 31, 2014 | shares
0.0072 Delaware
Exercise Price	$ 0.0072
Number of Shares | shares	123,828
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0072
Exercised at December 31, 2014 | shares
0.0056 Delaware
Exercise Price	$ 0.0056
Number of Shares | shares	375,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0056
Exercised at December 31, 2014 | shares
0.0070 Delaware
Exercise Price	$ 0.007
Number of Shares | shares	250,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.007
Exercised at December 31, 2014 | shares
0.0070 Delaware
Exercise Price	$ 0.007
Number of Shares | shares	373,714
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.007
Exercised at December 31, 2014 | shares
0.0041 Delaware
Exercise Price	$ 0.0041
Number of Shares | shares	850,244
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0041
Exercised at December 31, 2014 | shares
0.0045 Delaware
Exercise Price	$ 0.0045
Number of Shares | shares	2,000,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0045
Exercised at December 31, 2014 | shares
0.0024 Delaware
Exercise Price	$ 0.0024
Number of Shares | shares	150,000
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0024
Exercised at December 31, 2014 | shares
0.0010 Delaware
Exercise Price	$ 0.001
Number of Shares | shares	7,625,544
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.001
Exercised at December 31, 2014 | shares
0.0024 Delaware
Exercise Price	$ 0.0024
Number of Shares | shares	1,770,000
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0024
Exercised at December 31, 2014 | shares
0.0023 Delaware
Exercise Price	$ 0.0023
Number of Shares | shares	400,782
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0023
Exercised at December 31, 2014 | shares
0.0012 Delaware
Exercise Price	$ 0.0012
Number of Shares | shares	275,000
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0012
Exercised at December 31, 2014 | shares
0.0017 Delaware
Exercise Price	$ 0.0017
Number of Shares | shares	1,764,706
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0017
Exercised at December 31, 2014 | shares
0.0018 Delaware
Exercise Price	$ 0.0018
Number of Shares | shares	2,463,333
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0018
Exercised at December 31, 2014 | shares
0.0021 Delaware
Exercise Price	$ 0.0021
Number of Shares | shares	285,714
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0021
Exercised at December 31, 2014 | shares
0.0018 Delaware
Exercise Price	$ 0.0018
Number of Shares | shares	333,333
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0018
Exercised at December 31, 2014 | shares
0.0018 Delaware
Exercise Price	$ 0.0018
Number of Shares | shares	1,083,333
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0018
Exercised at December 31, 2014 | shares
0.0032 Delaware
Exercise Price	$ 0.0032
Number of Shares | shares	131,250
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0032
Exercised at December 31, 2014 | shares
0.0040 Delaware
Exercise Price	$ 0.004
Number of Shares | shares	2,250,000
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.004
Exercised at December 31, 2014 | shares
0.0040 Delaware
Exercise Price	$ 0.004
Number of Shares | shares	562,500
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.004
Exercised at December 31, 2014 | shares
0.0060 Delaware
Exercise Price	$ 0.006
Number of Shares | shares	390,000
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.006
Exercised at December 31, 2014 | shares
0.0070 Delaware
Exercise Price	$ 0.007
Number of Shares | shares	1,714,825
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.007
Exercised at December 31, 2014 | shares
0.0045 Delaware
Exercise Price	$ 0.0045
Number of Shares | shares	1,500,000
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0045
Exercised at December 31, 2014 | shares
0.0070 Delaware
Exercise Price	$ 0.007
Number of Shares | shares	1,714,825
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.007
Exercised at December 31, 2014 | shares
0.0070 Delaware
Exercise Price	$ 0.007
Number of Shares | shares	1,714,285
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.007
Exercised at December 31, 2014 | shares
0.0050 Delaware
Exercise Price	$ 0.005
Number of Shares | shares	1,500,000
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.005
Exercised at December 31, 2014 | shares

NOTE 8. STOCK OPTIONS AND SUB40

NOTE 8. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock subscription payable - current	$ 28,081	$ 55,882
Non employee stock options [Member]
Stock option exercised			20,000
Outstanding balance			$ 2,500
Option terms expiration	January 2,015		January 2,015
Options exercisable exercise price			$ 0.10
Option expired	30,038,041
Option granted	16,282,995
Dividend yield	0.00%		0.00%
Expected lives	5 years		5 years
Compensation expense	$ 27,731		$ 69,886
Non employee stock options [Member] | CA [Member]
Stock options outstanding					22,500
Non employee stock options [Member] | Minimum [Member]
Risk free interest rate	1.37%		1.55%
Volatility rate	172.00%		147.00%
Non employee stock options [Member] | Maximum [Member]
Risk free interest rate	1.68%		1.77%
Volatility rate	174.00%		178.00%
Non employee stock options [Member] | DA [Member]
Outstanding balance	$ 41,384,476	$ 30,038,041		$ 5,351,413	$ 29,678
Option granted	11,346,435	16,282,995	8,403,633	5,321,735	29,678
Risk free interest rate					0.80%
Dividend yield	0.00%	0.00%		0.00%	0.00%
Expected lives	5 years	5 years		5 years	5 years
Volatility rate					189.00%
Compensation expense	$ 3,603	$ 27,731		$ 145,997	$ 4,042
Non employee stock options [Member] | DA [Member] | Minimum [Member]
Risk free interest rate	1.03%	1.37%	1.55%	7.00%
Volatility rate	162.00%	172.00%	147.00%	179.00%
Non employee stock options [Member] | DA [Member] | Maximum [Member]
Outstanding balance			$ 13,755,046
Risk free interest rate	1.30%	1.68%	1.77%	14.00%
Dividend yield			0.00%
Expected lives			5 years
Volatility rate	167.00%	174.00%	178.00%	186.00%
Compensation expense			$ 69,886
Non employee stock options [Member] | CA [Member]
Outstanding balance					$ 22,500
Option terms expiration					January 2012 through January 2015
Option granted					29,678
Risk free interest rate					2.67%
Dividend yield					0.00%
Expected lives					5 years
Volatility rate					100.00%
Non employee stock options [Member] | CA [Member] | Minimum [Member]
Options exercisable exercise price					$ 0.10
Non employee stock options [Member] | CA [Member] | Maximum [Member]
Options exercisable exercise price					$ 0.15
Preferred Stock [Member]
Stock subscription payable - current	$ 14	$ 14
Common stock issued for stock subscription payment	1,388,575	1,388,575
Common Stock [Member]
Stock subscription payable - current	$ 28,067	$ 55,868
Common stock issued for stock subscription payment	87,084	6,049,578

NOTE 9. COMMON STOCK (Details N

NOTE 9. COMMON STOCK (Details Narrative) - USD ($)	Jun. 11, 2015	Jan. 21, 2016	Dec. 31, 2016	Dec. 31, 2015
Notes to Financial Statements
Stock issued to settle accrued interest, shares			1,000,000
Stock issued to settle accrued interest, value			$ 3,900
Stock issued for cash, Shares	834,408	5,000,000
Stock issued for cash, Amount	$ 1,502	$ 25,000	$ 25,000	$ 1,502
Common stock purchase price	$ 0.0018	$ 0.0050
Stock issued to settle accounts payable, shares		2,500,000
Stock issued to settle accounts payable, value		$ 9,750
Debt conversion price		$ 0.0039

NOTE 10. COMMITMENTS AND CONT42

NOTE 10. COMMITMENTS AND CONTINGENCIES (Details)	Dec. 31, 2016USD ($)
2,017	$ 49,200
2,018	49,200
2,019	24,600
2,020
2,021
Total	123,000
Operating Leases [Member]
2,017	49,200
2,018	49,200
2,019	24,600
2,020
2,021
Total	$ 123,000

NOTE 10. COMMITMENTS AND CONT43

NOTE 10. COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Note 10. Commitments And Contingencies Details Narrative
Rent expense	$ 52,420	$ 24,600